We are live on
!
Find out more
TCM
Tamarack Capital Management Portfolio holdings
AUM
$840M
1-Year Est. Return
19.47%
This Fund
S&P 500
This Quarter
Est. Return
+1.16%
1 Year Est. Return
+19.47%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$490M
AUM Growth
+$89.3M
(+22%)
Cap. Flow
+$93.4M
Cap. Flow
% of AUM
19.06%
Top 10 Holdings %
Top 10 Hldgs %
72.93%
Holding
34
New
10
Increased
14
Reduced
5
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AEGR
Aegerion Pharmaceuticals
AEGR
|
+$14.9M |
| 2 |
SPNC
Spectranetics Corp
SPNC
|
+$14.5M |
| 3 |
ELGX
Endologix Inc
ELGX
|
+$12.6M |
| 4 |
Teva Pharmaceuticals
TEVA
|
+$12.6M |
| 5 |
Ironwood Pharmaceuticals
IRWD
|
+$10.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
INSY
Insys Therapeutics, Inc.
INSY
|
+$19.8M |
| 2 |
BMR
BIOMED REALTY TRUST INC
BMR
|
+$11.3M |
| 3 |
CONMED
CNMD
|
+$6.44M |
| 4 |
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
|
+$3.36M |
| 5 |
NXTM
NxStage Medical Inc.
NXTM
|
+$1.96M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 50.32% |
| 2 | Technology | 2.54% |
| 3 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
CONMED
CNMD
$1.41B
| $2.18M | 0.44% |
50,000
-142,000
| -74% | -$6.44M |
|
27
Bio-Rad Laboratories Class A
BIO
$8.74B
| $1.93M | 0.39% |
+16,369
| New | +$2M |
|
|
AMAG
28
DELISTED
AMAG Pharmaceuticals
AMAG
| $1.22M | 0.25% |
+64,080
| New | +$1.18M |
|
|
29
CALL
CONMED
CNMD
$1.41B
| $227K | 0.05% |
+5,200
| New | +$236K |
|
30
CALL
Johnson & Johnson
JNJ
$617B
| – | – |
-175,000
| Closed | -$17.2M |
|
31
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$784B
| – | – |
-350,000
| Closed | -$65.5M |
|
|
OXFD
32
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| – | – |
-167,625
| Closed | -$3.36M |
|
|
INSY
33
DELISTED
Insys Therapeutics, Inc.
INSY
| – | – |
-954,282
| Closed | -$19.8M |
|
|
BMR
34
DELISTED
BIOMED REALTY TRUST INC
BMR
| – | – |
-550,000
| Closed | -$11.3M |
|
Similar funds
RI
CWA
GHF
F
TRV
BMCMI
GACM
AH
Tamarack Capital Management's Q2 2014 Portfolio in Review
As of Q2 2014, Tamarack Capital Management held 34 positions worth $490M, up 22% from $401M the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Tamarack Capital Management deployed $93.4M of net new capital in Q2 2014, opening 10 new positions and adding to 14 existing holdings. Its largest new stake was Aegerion Pharmaceuticals: 400,000 shares worth $11.7M.
By sector, the portfolio is most concentrated in Healthcare at 50% of assets, up from 44% a quarter earlier, followed by Technology and Real Estate.
On the sell side, the largest reduction was CONMED, an estimated $6.44M trimmed.
- Tamarack Capital Management's largest Q2 2014 buy was Aegerion Pharmaceuticals: 400,000 shares worth $11.7M.
- Tamarack Capital Management added most to Spectranetics Corp in Q2 2014, an estimated $14.5M increase.
- Tamarack Capital Management's biggest Q2 2014 reduction was CONMED, cutting an estimated $6.44M.
- Tamarack Capital Management fully exited Insys Therapeutics, Inc. in Q2 2014, selling an estimated $19.8M.
- Tamarack Capital Management's ten largest holdings make up 73% of its $490M portfolio in Q2 2014.
- Tamarack Capital Management opened 10 new positions and closed 5 in Q2 2014.
- Tamarack Capital Management's portfolio value rose 22% quarter-over-quarter to $490M.
Based on Tamarack Capital Management's 13F filing for Q2 2014, filed 15 Aug 2014.